Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cyteir Therapeutics, Inc.CYT · Entity 92707 | General Counsel | February 03, 2023 | February 07, 2023 |
| Dianthus Therapeutics, Inc. /DE/DNTH · Entity 1813 | SVP, General Counsel and Sec. | August 13, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cyteir Therapeutics, Inc.
Report date February 03, 2023 · Filed February 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2033-02-03 | Direct | 96,100 |
Reported balance
After 2023-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-03 · Grant · Acquired 96,100 · Balance 96,100 F1: The shares of common stock underlying this stock option award vest as to 2.083% in 48 equal monthly installments after the grant date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying this stock option award vest as to 2.083% in 48 equal monthly installments after the grant date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.
Dianthus Therapeutics, Inc. /DE/
Report date August 13, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,000 |
Reported balance
After 2026-08-13 transaction · row 1
1 source rowRow 1 · 2026-08-13 · Exercise / conversion · Acquired 15,000 · Balance 15,000 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.17 · Expires 2033-06-28 | Direct | 73,240 |
Reported balance
After 2026-08-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-13 · Exercise / conversion · Disposed 15,000 · Balance 73,240 F1: The shares of common stock underlying this stock option award vested as to 25% of the shares on June 20, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying this stock option award vested as to 25% of the shares on June 20, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACCELERON PHARMA INC
Report date November 19, 2021 · Filed November 22, 2021
Section 16 reporting ended · disclosed 2021-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Other · Disposed 23,423 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $40.37 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 6,700 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $40.61 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-19 · Disposition to issuer · Disposed 7,650 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $41.64 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-19 · Disposition to issuer · Disposed 8,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $52.99 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-19 · Disposition to issuer · Disposed 24,334 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $115.53 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-19 · Disposition to issuer · Disposed 18,806 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2026 Filed Aug 14, 2026 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $18.17 | $0.00 |
DisclosureSEC source: 0001778623-26-000009 · ownership.xml · derivative · entry 2 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,240 Underlying: Common Stock · 15,000 shares Expires 2033-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vested as to 25% of the shares on June 20, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| August 13, 2026 Filed Aug 14, 2026 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 15,000 | $18.17 | $272,550.00 |
DisclosureSEC source: 0001778623-26-000009 · ownership.xml · nonDerivative · entry 1 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 21:08 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,167 | $0.00 Strike: $17.88 | $0.00 |
DisclosureSEC source: 0001778623-26-000007 · ownership.xml · derivative · entry 7 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 16,167 shares Expires 2034-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F5 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 21:08 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 16,167 | $110.38 | $1,784,513.46 |
DisclosureSEC source: 0001778623-26-000007 · ownership.xml · nonDerivative · entry 5 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.00 to $110.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 21:08 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 16,167 | $17.88 | $289,065.96 |
DisclosureSEC source: 0001778623-26-000007 · ownership.xml · nonDerivative · entry 4 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 21:08 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,833 | $0.00 Strike: $17.88 | $0.00 |
DisclosureSEC source: 0001778623-26-000007 · ownership.xml · derivative · entry 6 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,167 Underlying: Common Stock · 3,833 shares Expires 2034-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F5 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 21:08 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 616 | $111.18 | $68,486.88 |
DisclosureSEC source: 0001778623-26-000007 · ownership.xml · nonDerivative · entry 3 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.08 to $111.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 21:08 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 3,217 | $110.61 | $355,832.37 |
DisclosureSEC source: 0001778623-26-000007 · ownership.xml · nonDerivative · entry 2 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 616 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.07 to $111.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 21:08 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 3,833 | $17.88 | $68,534.04 |
DisclosureSEC source: 0001778623-26-000007 · ownership.xml · nonDerivative · entry 1 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $17.88 | $0.00 |
DisclosureSEC source: 0001778623-26-000005 · ownership.xml · derivative · entry 4 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 30,000 shares Expires 2034-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F4 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 13,229 | $81.38 | $1,076,576.02 |
DisclosureSEC source: 0001778623-26-000005 · ownership.xml · nonDerivative · entry 3 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.00 to $81.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | SaleCommon Stock | 16,771 | $80.34 | $1,347,382.14 |
DisclosureSEC source: 0001778623-26-000005 · ownership.xml · nonDerivative · entry 2 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,229 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.00 to $80.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | Exercise / conversionCommon Stock | 30,000 | $17.88 | $536,400.00 |
DisclosureSEC source: 0001778623-26-000005 · ownership.xml · nonDerivative · entry 1 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 22:41 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $52.46 | $0.00 |
DisclosureSEC source: 0001778623-26-000002 · ownership.xml · derivative · entry 1 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-02-03 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:23 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $22.07 | $0.00 |
DisclosureSEC source: 0000950170-25-013488 · ownership.xml · derivative · entry 1 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-02-02 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| May 23, 2024 Filed May 29, 2024 00:05 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0000950170-24-065566 · ownership.xml · derivative · entry 1 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:46 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $17.88 | $0.00 |
DisclosureSEC source: 0000950170-24-007994 · ownership.xml · derivative · entry 1 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2034-01-23 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 16:14 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | GrantStock Option (Right to Buy) · Derivative | 96,100 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001209191-23-007500 · doc4.xml · derivative · entry 1 Veness Adam M · CIK 0001778623 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,100 Underlying: Common Stock · 96,100 shares Expires 2033-02-03 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest as to 2.083% in 48 equal monthly installments after the grant date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date. Read SEC document |
| May 02, 2022 Filed May 4, 2022 16:22 UTC | Cyteir Therapeutics, Inc. CYT · Entity 92707 | GrantStock Option (Right to buy) · Derivative | 177,000 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001209191-22-027079 · doc4.xml · derivative · entry 1 Veness Adam M · CIK 0001778623 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,000 Underlying: Common Stock · 177,000 shares Expires 2032-04-25 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest as to 25% on April 25, 2023, and 2.083% in 36 monthly installments thereafter, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 09:05 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 18,806 | Not disclosed Strike: $115.53 | Not disclosed |
DisclosureSEC source: 0001104659-21-142271 · tm2133601-5_4seq1.xml · derivative · entry 6 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,806 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 09:05 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 24,334 | Not disclosed Strike: $52.99 | Not disclosed |
DisclosureSEC source: 0001104659-21-142271 · tm2133601-5_4seq1.xml · derivative · entry 5 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,334 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 09:05 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 8,500 | Not disclosed Strike: $41.64 | Not disclosed |
DisclosureSEC source: 0001104659-21-142271 · tm2133601-5_4seq1.xml · derivative · entry 4 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 09:05 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 7,650 | Not disclosed Strike: $40.61 | Not disclosed |
DisclosureSEC source: 0001104659-21-142271 · tm2133601-5_4seq1.xml · derivative · entry 3 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,650 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 09:05 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 6,700 | Not disclosed Strike: $40.37 | Not disclosed |
DisclosureSEC source: 0001104659-21-142271 · tm2133601-5_4seq1.xml · derivative · entry 2 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,700 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 09:05 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | OtherCommon Stock | 23,423 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-142271 · tm2133601-5_4seq1.xml · nonDerivative · entry 1 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 16:15 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionOption to Purchase Common Stock · Derivative | 4,500 | $0.00 Strike: $29.37 | $0.00 |
DisclosureSEC source: 0001179110-21-010095 · edgar.xml · derivative · entry 2 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,500 shares Expires 2024-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vested as to 25% of the shares on July 14, 2015 and the remaining shares vested in equal quarterly installments over the following three years thereafter. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 16:15 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 4,500 | $29.37 | $132,165.00 |
DisclosureSEC source: 0001179110-21-010095 · edgar.xml · nonDerivative · entry 1 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,423 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 18:08 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionOption to Purchase Common Stock · Derivative | 1,450 | $0.00 Strike: $41.20 | $0.00 |
DisclosureSEC source: 0001179110-21-008895 · edgar.xml · derivative · entry 5 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,450 shares Expires 2025-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: The shares of common stock underlying this stock option award vested in equal quarterly installments over the four years after January 1, 2015. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 18:08 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionOption to Purchase Common Stock · Derivative | 5,200 | $0.00 Strike: $30.17 | $0.00 |
DisclosureSEC source: 0001179110-21-008895 · edgar.xml · derivative · entry 4 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,200 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: The shares of common stock underlying this stock option award vested in equal quarterly installments over the four years after January 1, 2017. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 18:08 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 6,650 | $150.05 | $997,832.50 |
DisclosureSEC source: 0001179110-21-008895 · edgar.xml · nonDerivative · entry 3 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,923 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.36 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 18:08 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 1,450 | $41.20 | $59,740.00 |
DisclosureSEC source: 0001179110-21-008895 · edgar.xml · nonDerivative · entry 2 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 18:08 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 5,200 | $30.17 | $156,884.00 |
DisclosureSEC source: 0001179110-21-008895 · edgar.xml · nonDerivative · entry 1 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 09, 2021 Filed Sep 9, 2021 17:07 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 1,407 | $130.00 | $182,910.00 |
DisclosureSEC source: 0001179110-21-008690 · edgar.xml · nonDerivative · entry 3 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,923 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 17:07 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 6 | $130.00 | $780.00 |
DisclosureSEC source: 0001179110-21-008690 · edgar.xml · nonDerivative · entry 2 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,330 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 17:07 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Tax withholdingCommon Stock | 587 | $129.36 | $75,934.32 |
DisclosureSEC source: 0001179110-21-008690 · edgar.xml · nonDerivative · entry 1 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,336 Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 18:53 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Tax withholdingCommon Stock | 108 | $126.69 | $13,682.52 |
DisclosureSEC source: 0001179110-21-006496 · edgar.xml · nonDerivative · entry 1 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,923 Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 19:50 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 18,806 | $0.00 Strike: $115.53 | $0.00 |
DisclosureSEC source: 0001179110-21-001125 · edgar.xml · derivative · entry 2 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,806 Underlying: Common Stock · 18,806 shares Expires 2031-01-29 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2021. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 19:50 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantCommon Stock | 4,868 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001125 · edgar.xml · nonDerivative · entry 1 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,031 Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 19:12 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 100 | $124.30 | $12,430.00 |
DisclosureSEC source: 0001179110-21-000373 · edgar.xml · nonDerivative · entry 4 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,163 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 19:12 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 56 | $122.93 | $6,884.08 |
DisclosureSEC source: 0001179110-21-000373 · edgar.xml · nonDerivative · entry 3 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,263 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 19:12 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 1,900 | $122.46 | $232,674.00 |
DisclosureSEC source: 0001179110-21-000373 · edgar.xml · nonDerivative · entry 2 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,319 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.86 to $122.85 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 19:12 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Tax withholdingCommon Stock | 942 | $124.31 | $117,100.02 |
DisclosureSEC source: 0001179110-21-000373 · edgar.xml · nonDerivative · entry 1 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,219 Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 17:49 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 929 | $89.85 | $83,470.65 |
DisclosureSEC source: 0001179110-20-009643 · edgar.xml · nonDerivative · entry 2 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,161 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.68 to $90.28 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| September 08, 2020 Filed Sep 9, 2020 17:49 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 1,071 | $89.20 | $95,533.20 |
DisclosureSEC source: 0001179110-20-009643 · edgar.xml · nonDerivative · entry 1 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,090 F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.63 to $89.59 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| April 08, 2020 Filed Apr 10, 2020 17:30 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionOption to Purchase Common Stock · Derivative | 6,000 | $0.00 Strike: $27.97 | $0.00 |
DisclosureSEC source: 0001179110-20-004830 · edgar.xml · derivative · entry 7 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2026-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: The shares of common stock underlying this stock option award vested in equal quarterly installments over the four years after January 1, 2016. Read SEC document |
| April 08, 2020 Filed Apr 10, 2020 17:30 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 417 | $87.53 | $36,500.01 |
DisclosureSEC source: 0001179110-20-004830 · edgar.xml · nonDerivative · entry 6 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,161 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.39 to $87.60 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4. Read SEC document |
| April 08, 2020 Filed Apr 10, 2020 17:30 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 1,100 | $86.69 | $95,359.00 |
DisclosureSEC source: 0001179110-20-004830 · edgar.xml · nonDerivative · entry 5 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,578 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.35 to $87.29 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4. Read SEC document |
| April 08, 2020 Filed Apr 10, 2020 17:30 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 2,883 | $85.77 | $247,274.91 |
DisclosureSEC source: 0001179110-20-004830 · edgar.xml · nonDerivative · entry 4 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,678 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.30 to $86.11 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document |
| April 08, 2020 Filed Apr 10, 2020 17:30 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 700 | $84.62 | $59,234.00 |
DisclosureSEC source: 0001179110-20-004830 · edgar.xml · nonDerivative · entry 3 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,561 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.18 to $85.12 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| April 08, 2020 Filed Apr 10, 2020 17:30 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 900 | $83.49 | $75,141.00 |
DisclosureSEC source: 0001179110-20-004830 · edgar.xml · nonDerivative · entry 2 Veness Adam M · CIK 0001778623 · SVP, General Counsel and Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,261 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.99 to $83.95 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.